The importance of Rem-L being the only MSC in P3 is not being appreciated by the market - so not in the current SP at all!
NIH could have funded anyone...
Why did they choose a largely unknown Australian company's product?
Because the EAP was an overwhelming success.
Only weeks to go to see if this is repeated/ shows up in an RCT.
I'm thinking 60% would suit everyone:
1. Sufficient data
2. Shortened trial
3. Last line defense against covid
Bring it on!
Cell Therapy News/Articles, page-7214
-
- There are more pages in this discussion • 11,045 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |